Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Laboratory Test Abnormalities
Timeframe: During study treatment (maximum up to 118 months)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Timeframe: From start of the study intervention up to 28 days after last dose of the study intervention or until study completion or withdrawal, whichever is longer (maximum up to 118 months from start of study intervention)
Absolute Values of Body Weight at Baseline
Timeframe: At Baseline
Absolute Value of Body Weight at Month 12 and Its Change From Baseline at Month 12
Timeframe: Baseline, Month 12
Absolute Value of Body Weight at Month 24 and Its Change From Baseline at Month 24
Timeframe: Baseline, Month 24
Absolute Value of Body Weight at Month 36 and Its Change From Baseline at Month 36
Timeframe: Baseline, Month 36
Absolute Value of Body Weight at Month 48 and Its Change From Baseline at Month 48
Timeframe: Baseline, Month 48
Absolute Value of Body Weight at Month 60 and Its Change From Baseline at Month 60
Timeframe: Baseline, Month 60
Absolute Value of Body Weight at Month 72 and Its Change From Baseline at Month 72
Timeframe: Baseline, Month 72
Absolute Value of Body Weight at Month 84 and Its Change From Baseline at Month 84
Timeframe: Baseline, Month 84
Absolute Value of Height at Baseline
Timeframe: At Baseline
Absolute Value of Height at Month 12 and Its Change From Baseline at Month 12
Timeframe: Baseline, Month 12
Absolute Value of Height at Month 24 and Its Change From Baseline at Month 24
Timeframe: Baseline, Month 24
Absolute Value of Height at Month 36 and Its Change From Baseline at Month 36
Timeframe: Baseline, Month 36
Absolute Value of Height at Month 48 and Its Change From Baseline at Month 48
Timeframe: Baseline, Month 48
Absolute Value of Height at Month 60 and Its Change From Baseline at Month 60
Timeframe: Baseline, Month 60
Absolute Value of Height at Month 72 and Its Change From Baseline at Month 72
Timeframe: Baseline, Month 72
Absolute Value of Height at Month 84 and Its Change From Baseline at Month 84
Timeframe: Baseline, Month 84
Number of Participants According to Tanner Stage at Baseline
Timeframe: At Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap)
Number of Participants With Shift in Tanner Stage From Baseline to Month 12
Timeframe: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 12
Number of Participants With Shift in Tanner Stage From Baseline to Month 24
Timeframe: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 24
Number of Participants With Shift in Tanner Stage From Baseline to Month 36
Timeframe: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 36
Number of Participants With Shift in Tanner Stage From Baseline to Month 48
Timeframe: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 48
Number of Participants With Shift in Tanner Stage From Baseline to Month 60
Timeframe: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 60
Number of Participants With Shift in Tanner Stage From Baseline to Month 72
Timeframe: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 72
Number of Participants With Shift in Tanner Stage From Baseline to Month 84
Timeframe: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 84